INS and type 2 diabetes mellitus: Administration of heme, in the form of repeated intraperitoneal injections of hemin ameliorates experimental type 2 diabetes by reducing systemic inflammation, augmenting β-cell insulin secretion, improving peripheral insulin sensitisation, increasing serum adiponectin levels and by activating skeletal muscle 5′ adenosine monophosphate-activated protein kinase (AMPK) [3]–[5].